# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

> **NCT05590338** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** GSK1070806
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05590338
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-04
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-12-28
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590338, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05590338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*